CureVac's Potential Has Wall Street Sending Mixed Signals
While there seems general acknowledgment that CureVac (NASDAQ: CVAC) can still win a seat at the COVID-19 vaccine table -- and arguably, take up a lot of room at that table -- Wall Street remains largely unimpressed by the biotech at the moment.
Analysts from both Guggenheim Securities and Credit Suisse (NYSE: CS) weighed in on CureVac Monday, and neither saw its outlook as being especially robust.
Image source: Getty Images.
Source Fool.com
